Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for LP-300 in Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
05/15/26:- HARMONIC Type C outcome successful; protocol amendments accepted. Additional Ph2 data expected H2 2026. 05/19/26:- FDA supported HARMONIC protocol changes. Additional Ph2 data expected in H2 2026. 06/02/26:- Updated Ph2 HARMONIC data show 8.9-month median PFS in L858R. Dosing extended; more data expected H2 2026. 08/14/26:- HARMONIC data showed 8.9-month L858R median progression-free survival. Additional Phase 2 data is expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.